Holen Sie sich die Stockscreener-App
1.59
0.00%
0.00
Schlusskurs vom Vortag:
$1.59
Offen:
$1.6
24-Stunden-Volumen:
8,126
Relative Volume:
0.03
Marktkapitalisierung:
$64.15M
Einnahmen:
$1.88M
Nettoeinkommen (Verlust:
$-15.57M
KGV:
-3.975
EPS:
-0.4
Netto-Cashflow:
$-50.09M
1W Leistung:
-1.24%
1M Leistung:
-18.04%
6M Leistung:
-31.17%
1J Leistung:
-2.45%
1-Tages-Spanne:
$1.56
$1.61
1-Wochen-Bereich:
$1.38
$1.675
52-Wochen-Spanne:
$0.98
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
Firmenname
Beyondspring Inc
Sektor
Branche
Telefon
646-528-4184
Adresse
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Vergleichen Sie BYSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.56 | 65.38M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.67 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.37 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.75 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.69 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-12-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | Eingeleitet | BofA Securities | Buy |
| 2020-12-29 | Eingeleitet | Evercore ISI | Outperform |
| 2020-02-07 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | Nomura | Buy |
| 2019-12-03 | Eingeleitet | William Blair | Outperform |
| 2019-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-30 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-10-25 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Beyondspring Inc Aktie (BYSI) Neueste Nachrichten
Can BeyondSpring Inc. stock maintain operating marginsGlobal Markets & Momentum Based Trading Ideas - ulpravda.ru
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) - Defense World
Breakout Zone: How BeyondSpring Inc stock compares to market leaders2025 EndofYear Setup & Short-Term Trading Alerts - moha.gov.vn
Why BeyondSpring Inc. stock could benefit from AI revolutionVolatility Index Analysis & Free Significant Capital Appreciation - bollywoodhelpline.com
S P Trends: Does BeyondSpring Inc stock trade at a discount to peersMarket Movement Recap & Precise Swing Trade Alerts - moha.gov.vn
BeyondSpring Inc. (NASDAQ:BYSI) Sees Large Increase in Short Interest - MarketBeat
BeyondSpring (NASDAQ:BYSI) Shares Down 4.2% – Should You Sell? - Defense World
BeyondSpring (NASDAQ:BYSI) Trading Down 4.2%Should You Sell? - MarketBeat
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Krystal Biotech (NASDAQ:KRYS) and BeyondSpring (NASDAQ:BYSI) Critical Survey - Defense World
Will BeyondSpring Inc. stock benefit from infrastructure spendingJuly 2025 Trade Ideas & Consistent Growth Equity Picks - Улправда
Can BeyondSpring Inc. stock weather global recessionJuly 2025 Breakouts & Weekly Return Optimization Alerts - Улправда
Will BeyondSpring Inc. stock benefit from sector rotationJuly 2025 Macro Moves & Breakout Confirmation Alerts - DonanımHaber
Will BeyondSpring Inc. stock benefit from AI adoptionMarket Weekly Review & Weekly Chart Analysis and Guides - Улправда
Pharma News: Will BeyondSpring Inc. stock outperform tech sector in 2025Quarterly Trade Summary & Low Risk Investment Opportunities - moha.gov.vn
Beyondspring Delays Second Closings of Share Sale - TipRanks
BeyondSpring Inc. Announces Preferred Share Purchase Agreement - TradingView — Track All Markets
BeyondSpring (NASDAQ: BYSI) now expects SEED share Second Closings in 1H 2026 - Stock Titan
BYSI: Recent Business Developments Shape Market Outlook - StocksToTrade
BeyondSpring Inc. Stock Shows Upward Spike As Earnings Report Uncovers Surprises - StocksToTrade
BeyondSpring Stock Faces Challenges Amid Recent Market Dynamics - timothysykes.com
BeyondSpring Inc. Faces Financial Pressure in the Pharmaceutical Market - timothysykes.com
BYSI Stock Shows Turbulence Amid Financial Uncertainty - StocksToTrade
BYSI Stock Volatility Amidst Strategic Developments and Market Shifts - StocksToTrade
BeyondSpring presents phase 3 DUBLIN-3 data at ESMO Asia Congress - MSN
BYSI’s Stock Roller Coaster: What Happens Next? - StocksToTrade
BeyondSpring Inc.’s Market Shift: Analyzing Financial Trends and Price Movements - timothysykes.com
BeyondSpring’s Stock Gains Steam Amid Market Developments - timothysykes.com
BeyondSpring Inc. (BYSI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path - CoinCentral
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 - marketscreener.com
BYSI: BeyondSpring's Plinabulin Shows Promising Results in Phase 3 Trial - GuruFocus
BeyondSpring stock rises after positive Asian subset data from lung cancer trial - Investing.com Nigeria
BeyondSpring stock rises after positive Asian subset data from lung cancer trial By Investing.com - Investing.com South Africa
BeyondSpring reports positive Asian subset data for lung cancer drug By Investing.com - Investing.com Canada
BeyondSpring reports positive Asian subset data for lung cancer drug - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewswire
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC - TipRanks
BeyondSpring (BYSI) Reports Promising Results for Plinabulin in Lung Cancer Study - GuruFocus
BeyondSpring Announces Positive Phase 3 DUBLIN-3 Results for Plinabulin in NSCLC Patients Post Anti-PD-(L)1 Therapy and Plans for Global DUBLIN-4 Trial - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) DUBLIN-3 finds 15.8-month OS, fewer brain mets in NSCLC - Stock Titan
Why 22nd Century Group Inc stock could benefit from AI revolutionTrade Ideas & Accurate Buy Signal Notifications - moha.gov.vn
Finanzdaten der Beyondspring Inc-Aktie (BYSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beyondspring Inc-Aktie (BYSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sci | 10% Owner |
Oct 17 '25 |
Sale |
1.76 |
45,513 |
80,103 |
1,518,893 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 13 '25 |
Sale |
1.70 |
107,361 |
182,514 |
1,696,659 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 14 '25 |
Sale |
1.65 |
28,495 |
47,017 |
1,668,164 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 15 '25 |
Sale |
1.65 |
17,960 |
29,634 |
1,650,204 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 08 '25 |
Sale |
1.77 |
7,507 |
13,287 |
1,810,389 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 09 '25 |
Sale |
1.81 |
3,979 |
7,202 |
1,806,410 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 10 '25 |
Sale |
1.77 |
2,390 |
4,230 |
1,804,020 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 06 '25 |
Sale |
1.78 |
17,500 |
31,150 |
1,819,996 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 07 '25 |
Sale |
1.79 |
2,100 |
3,759 |
1,817,896 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 03 '25 |
Sale |
1.76 |
600 |
1,056 |
1,837,496 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):